✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
RO7034067 is an investigational drug.
There have been 6 clinical trials for RO7034067. The most recent clinical trial was a Phase 1 trial, which was initiated on October 20th 2016.
The most common disease conditions in clinical trials are Muscular Atrophy, Spinal, Muscular Atrophy, and Atrophy. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].
There are two US patents protecting this investigational drug and eighty international patents.
Recent Clinical Trials for RO7034067
|A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Ambulatory Children With Spinal Muscular Atrophy||Hoffmann-La Roche||Phase 2/Phase 3|
|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese Participants||Hoffmann-La Roche||Phase 1|
|A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy||Hoffmann-La Roche||Phase 2|
Top disease conditions for RO7034067
Top clinical trial sponsors for RO7034067
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|RO7034067||See Plans and Pricing||Compounds for treating spinal muscular atrophy||PTC Therapeutics, Inc. (South Plainfield, NJ) F. Hoffmann-La Roche AG (Basel, CH)||See Plans and Pricing|
|RO7034067||See Plans and Pricing||Compounds for treating spinal muscular atrophy||HOFFMANN-LA ROCHE INC. (Little Falls, NJ) PTC THERAPEUTICS, INC. (South Plainfield, NJ)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|RO7034067||Argentina||AR092794||2032-02-10||See Plans and Pricing|
|RO7034067||Australia||AU2013216870||2032-02-10||See Plans and Pricing|
|RO7034067||Australia||AU2017204248||2032-02-10||See Plans and Pricing|
|RO7034067||Brazil||BR112014019750||2032-02-10||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|